Enveric Biosciences, Inc. (ENVB)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.45 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Key numbers

Fiscal year 2019, ended 31 Dec 2019, as filed

Revenue

$39.91M

Net income

$2.41M

Free cash flow

$647.86K

Gross margin

20.4%

Operating margin

-5.8%

Net margin

-6.0%

Revenue growth, 1 yr

-7.2%

Revenue and net income

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first

All of them →

Date	Insider	Type	Value	Of own stake
15 Sep 2023	PASQUALONE FRANK Director	Bought	$2.14K	opened
16 Nov 2018	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10% owner	Sold, plan not stated	$29.55K	4.3%
16 Nov 2018	Lokesh Sikaria Trust Dated 12/14/2012 10% owner	Sold, plan not stated	$29.55K	4.3%
16 Nov 2018	Sikaria Lokesh 10% owner	Sold, plan not stated	$29.55K	4.3%
16 Nov 2018	Sikaria Chanda 10% owner	Sold, plan not stated	$29.55K	4.3%
17 Jul 2018	Devanur Giri 10% owner	Sold, plan not stated	$226.63K	5.4%

Clue Score

How it works

35out of 100

Profitability 33

Financial strength 35

Growth 25

Insiders 50

Strongest on insiders (50), weakest on growth (25). A score of the business, not of the price.

What insiders did

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan

Every insider, every trade →

Profile

Sector: Health care
Industry: Pharmaceutical Preparations
Country: United States
SEC filings: EDGAR →